Cigna Demands Counseling for Breast Test in Myriad Threat

Cigna Corp. will become the first U.S. health insurer to require genetic counseling nationwide before it pays for tests for hereditary breast and ovarian cancer, a move that may threaten sales for Myriad Genetics Inc.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.